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Abstract
Cancer science is a heavily researched and rapidly changing field. Cutting edge research
consistently reveals unique features of tumors that can be exploited for treatment. For
example, it is well known that cells of varying tumor types have unique molecular
markers and cell-surface receptors - fingerprints of sorts - that set cancerous cells apart
from healthy cells. Furthermore, the tumor microenvironment has been explored to the
point that its unique fluid mechanical and biochemical properties are well understood in
the context of tumor growth and survival. However, very little of this research has
penetrated clinical medicine. The purpose of this thesis is to present a recent concept in
cancer therapy: an anti-cancer nanocell that is capable of the spatial and temporal
targeting of drugs to tumor cells. The combination of targeting mechanisms designed
into the nanocell is a product of our current understanding of tumors. The design serves
to improve the effectiveness of inexpensive, out-of-patent cytotoxic and anti-angiogenic
drugs to standards representative of modern research. Efforts towards improving the
efficiency of the nanocell, with regards to both drug loading and tumor cell targeting, are
presented and discussed. The synthesis of various polymer-ligand conjugates for use in
the improved nanocell is reported, as is the development of a prodrug consisting of a
generation three polyamidoamine dendrimer conjugated to methotrexate via an ester
bond; cell studies demonstrating the effectiveness of the prodrug are included. The
expandability of the nanocell is also explored, because ultimately, the nanocell must be
robust enough to accommodate both tumor-type and population variability.
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Chapter 1
Introduction
1.1 Background
Cancer is a leading cause of death in the United States; it accounts for 23% of all
deaths in the nation. The lifetime probability of getting cancer is nearly 50% for men and
33% for women. For children, the probability of getting cancer between the ages of zero
and fourteen is 15%. While the mortality of the disease varies significantly depending on
the type of cancer, the time of diagnosis, and patient demographic, the treatments
currently available for all types of cancers are fairly unsophisticated. They are not
wholly specific for cancer tissue microenvironments and they, in general, do not have
spectacular cure rates. Furthermore, cancer survival rates have not improved appreciably
in the past 50 years (all statistics from The American Cancer Society, 2004). As cancer
awareness rises and diagnostic methods improve, the need to develop more effective
treatments for cancer is ever more emphasized.
Currently, there exist several different options for cancer treatment, and most
cancer patients undergo some combination of the available therapies.
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1.1.1 Current Treatment Options
Surgery: surgery is a procedure performed on nearly all cancer patients as a
diagnostic procedure. It is also used as a treatment; when it is, it is usually accompanied
by radiation therapy, chemotherapy, and/or anti-angiogenesis therapy. The objective of a
surgical anti-cancer intervention is to remove as much of the primary tumor as possible,
and then allow ionizing radiation or chemotherpeutic agents to kill the remaining tumor
cells. The primary drawback of surgery is that it is invasive, it may result in physical
abnormalites, and it also involves the side-effects of therapies that it is combined with.
Furthermore, a surgical intervention targets primary tumors only; smaller metastases are
generally not treated by surgery. In fact, research has shown that the surgical resection of
a primary tumor can spark the growth of dormant metastatic tumors, due to the loss of
endogenous angiogenesis inhibitors produced by the primary tumor [O'Riley et al.,
1994].
Radiation Therapy: radiation therapy is a very common form of treatment in
which tumors are targeted and irradiated by a source of ionizing radiation; approximately
half of all cancer patients receive some form of the treatment. It was thought that the
primary action of radiation therapy is to cause mutations in the DNA of irradiated cells,
and thereby induce apoptosis during the replication phase of those cells' lives. However,
recent research suggests that the apoptotic effects of ionizing radiation arise from
intercellular signals that originate from irradiated endothelial cells [Gorsky et al. 1999].
Generally, radiotherapy is administered externally via an IR producing machine,
or internally via implanted sources of IR, depending on the type of tumor being treated.
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Radiation therapy is most often used to treat primary tumors. One benefit of radiation
therapy over surgical resection is that the pro-metastatic effect of the surgical treatment
of primary tumors is not observed following radiation therapy [Hartfor et al., 2000].
However, a significant disadvantage of radiation therapy is that it damages the normal
tissue surrounding the tumor. As such, there is a strong research push to develop tumor-
targeted radiosensitizers, normal tissue-radioprotectors, and the technology to precisely
shape radiation pulses such that they are absorbed in a preselected region.
Chemotherapy: chemotherapy is the administration of cytotoxic drugs that target
and cause lethal damage to cells undergoing mitosis. Because cancer cells are dividing
much more rapidly than most other cells in the body, chemotherapeutic drugs are
particularly effective against tumors. However, these drugs can also affect normal,
rapidly dividing cells, including bone marrow cells and cells of the gastrointestinal tract.
Thus, determining the correct dosage is very important, and will depend on both the
tumor and the patient.
Other: more modern anti-cancer therapies also exist, though most of them are in
clinical trials, or being researched heavily. These therapies include anti-angiogenesis
therapy, immunotherapy, photodynamic therapy (PDT), and most recently,
pharmaceuticals that target important signaling pathways in specifc tumor cell types. Of
these options, anti-angiogenesis therapy has received the most attention, as it has shown
significant promise when combined with radiotherapy and chemotherapy. The first anti-
angiogenesis drug, Avastin (bevacizumab) has already been approved for use with
chemotherapeutic agents.
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Combination Therapies: combination therapies are among the most effective
and widely used forms of cancer treatment available. Physicians implement such
therapies by strategically combining multiple treatment modalities in order to eliminate a
given tumor. Nearly all cancer patients today receive some form of multi-modal therapy.
The combination of surgery and radiation therapy was already mentioned above, but
chemotherapy is also often used in conjunction with radiation therapy and/or surgery.
Combination approaches involving chemotherapy are of particular interest,
because of their widespread use. In the case of chemotherapy alone, cytotoxic drugs are
not as effective in the center of a tumor as they are on the tumor periphery. The decline
in effectiveness is due in part to abnormalities in the vasculature and interstitial
environments of tumors; such abnormalities prevent chemotherapeutic agents from
readily diffusing to the center of the tumor [Jain 1997]. However, it is also due to the fact
that cells at the center of a tumor do not divide as rapidly as cells at the periphery
(cytotoxic drugs target rapidly dividing cells). Thus, to effectively eliminate a tumor,
chemotherapy is often combined with different treatment modalities; its combination with
anti-angiogenesis therapy shows significant promise.
1.1.2 The Synergy of Chemotherapy and Anti-Angiogenic Agents
Cancer treatment is a heavily researched and rapidly changing field. In the clinic,
the combination of multiple treatment modalities is becoming the favored approach. Of
the various strategies used, the combination of chemotherapy and anti-angiogenesis
therapy is promising due to its effectiveness and lack of additional toxicity [Klement et
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al.]. However, certain challenges must be overcome before the combination treatment is
maximally effective.
In considering the combination of chemotherapy with anti-angiogenesis therapy,
it is important to consider a relatively new concept in cancer biology: the normalization
of a tumor's vasculature in response to anti-angiogenic drugs. For some time, the
conventional belief regarding anti-angiogenesis therapy held that the administration of
angiogenesis inhibitors resulted in the destruction of a tumor's vasculature, and little
more. Consequently, anti-angiogenesis therapy would starve a tumor to of oxygen and
nutrients, and inhibit its growth and survival. However, recent research suggests that, in
the course of destroying tumor vasculature, certain anti-angiogenic agents can actually
cause the vasculature to become more "normal" and efficient at delivering nutrients for a
brief period of time [Jain 2005]. In brain tumors, this was shown to happen through
increased pericyte coverage and a corresponding activation of matrix metalloproteinases
[Winkler et al. 2004]. The transient normalization provided by antiangiogenic agents
can alleviate the hypoxic, high fluid pressure microenvironments of tumors and also
allow for improved drug delivery to the tumor interior. It has become increasingly
apparent that the window of normalization provided by anti-angiogenesis agents, such as
VEGFR-2 antibody and thalidomide, can be used to optimize the response of tumors to
cytotoxic therapies [Tong et al. 2004, Ansiaux et al. 2005].
After the transient phase of vascular normalization, the tumor becomes more
hypoxic, and various stress-response mechanisms are activated. In particular, hypoxia
induces the accumulation and activation of hypoxia-inducible factor-la (HIF-la)
[Carameliet et al. 1998]. HIF-lat accumulation and activation is known to increase
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tumor cell chemotherapy resistance [Semenza et al. 2000]. Also, as expected, the
regression of the tumor vasculature beyond the normalized state results in a decrease in
the effectiveness of the blood-based delivery of substances to the center of the tumor.
Two major problems exist in the combination of chemotherapy with anti-
angiogenesis therapy. First, because the therapies are not administered in a time-
controlled manner, such that the cytotoxic drug is delivered while the tumor vasculature
is in a normalized state, the effectiveness of chemotherapy is reduced both by diffusion
limitations and by the HIF-la mediated stress-response mechanism discussed above.
Second, because neither cytotoxic drugs nor anti-angiogenic drugs are presently targeted
to tumor cells, the combination therapy acts on any rapidly dividing cell or developing
vascular network (germ cells, bone marrow cells, hair follicles, etc.). The side-effects
due to such indiscriminate drug delivery can be painful and debilitating.
However, if the two therapies are strategically administered, the combination
treatment can be beneficially synergistic. In an ideal situation, the cytotoxic and anti-
angiogenic drugs would be delivered specifically to tumor microenvironments, and the
delivery would occur during phases of vascular normalization. The typical side-effects of
indiscriminate intravenous treatment would be avoided, while higher intratumoral
concentrations of the administered drugs could be achieved. To attain this synergy with
the current arsenal of FDA-approved anti-cancer drugs, a novel way of spatially and
temporally targeting anti-cancer drugs is required.
Spatial tumor targeting can be achieved by taking advantage of the increased
porosity of tumor vasculature. By designing a delivery vehicle that can pass through the
large pores in tumor blood vessels, but not through the smaller pores of normal vessels, a
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fair amount of spatial tumor targeting can be achieved [Hobbs et al. 1998, Yuan et al.
1995]. Furthermore, such targeting can be enhanced by the use of ligands that target
specific cell-surface receptors that are over expressed on tumor cells. Folic acid is one
such ligand [Hilgenbrink and Low, 2005], because it is involved in DNA synthesis, and
its cell-surface receptor over-expressed on many rapidly dividing cells.
Temporal targeting can be achieved through careful design of the delivery
vehicle. The vehicle would need to be capable of delivering both the anti-angiogenesis
and chemotherapy drugs at the same time, but then releasing them sequentially (anti-
angiogenesis drug first) in order to isolate the chemotherapeutic agent within the tumor.
The timescale of the process would have to allow anti-angiogenesis therapy to complete
before the cytotoxic drug takes effect, thereby trapping the cytotoxic drug in the tumor at
high concentrations.
1.2 Previous Work
A novel drug delivery vehicle that meets the criterion discussed above, termed the
"nanocell," has been developed in the Sasisekharan laboratory at MIT [Sengupta et al.
2005]. The nanocell is designed such that it delivers both cytotoxic and anti-angiogenic
drugs to tumors in the spatially and temporally targeted manner. The core of the nanocell
a nanoparticle that is composed of doxorubicin, a DNA-intercalating cytotoxic drug,
conjugated to the copolymer poly-(lactic-co-glycolic) acid (PLGA). A phospholipid
block-copolymer envelope encapsulates the inner nanoparticle, an anti-angiogenesis drug
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is held in between the nanoparticle and envelope. The anti-angiogenesis drug is
combretastatin A-4 phosphate, a biomolecule that disrupts vascular networks by inducing
tubulin depolymerization in endothelial cells. Upon synthesis, the nanocells range from
180-200 nanometers in diameter.
The design of the nanocell allows both spatial and temporal tumor targeting to be
achieved. Spatial tumor targeting is primarily a result of the size of the nanocell.
Compared to normal vasculature, the vasculature of growing tumors is known to be very
porous, with pore diameters ranging from 200 to 600 nanometers depending on tumor
type [Yuan et al., 1995]. Because normal vessel pores are much smaller, the 180 - 200
nanometer nanocell selectively diffuses into tumors from the bloodstream. Upon entering
a tumor, the nanocell envelope destabilizes, and both the free-floating anti-angiogenesis
drug and nuclear nanoparticle are released. The anti-angiogenesis drug acts immediately,
destabilizing the tumor vasculature as the treatment with the nanocell continues. During
the course of treatment, the tumor vasculature is normalized, and more and more
nanocells accumulate in the tumor; by the time the vasculature has been destroyed, high
intratumoral concentrations of the nuclear nanoparticles have been achieved. In time, the
nanoparticles slowly release the bound cytotoxic drug, and the combination therapy is
successfully completed.
Experiments on mice with tumor xenografts demonstrated that treatment with the
nanocells does indeed have the intended effects. Relative to control treatments, treatment
with the nanocell decreased HIF-la presence in tumors and also increased tumor cell
apoptosis rates. Furthermore, treatment with the nanocell resulted in a greater than
additive increase in mouse lifespan over the various control groups. The results were
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published by Sengupta et al. in 2005. The work represented the proof-of-concept
necessary to take the nanocell to industry.
Despite the success of the nanocell as designed, it was clear that certain aspects of
it needed to be improved before it could translate into a clinical setting. In particular,
there was an unmet need to develop a more efficient tumor cell targeting process and to
the loading mechanism of the nanocell.
1.3 Thesis Work
The bulk of this thesis describes the synthesis work and design principles
involved in meeting the needs described above. Three primary projects were undertaken:
1. To attempt to remake the nanocell envelope using chitosan, instead of using the
polyethylene glycol-disteroyl phosphatidylethanolamine (PEG-DSPE) liposome
from the original study.
2. To incorporate receptor targeting into the envelope of the nanocell, using folate as
a proof-of-concept targeting ligand.
3. To design a methotrexate prodrug using the polyamidoamine dendrimer, for
encapsulation within the nanocell.
The first project was undertaken to improve the cost-effectiveness of the nanocell.
Part of the motivation of the nanocell is that through its multiple layers of tumor
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targeting, the therapeutic index of various out-of-patent anti-cancer drugs can be
improved dramatically, thereby making cutting edge cancer treatment available to the
developing world at a relatively low price. The first project was undertaken to improve
the cost-effectiveness of the nanocell. Chitosan is a widely available, established
biomaterial that has already been used in several biomedical applications; indeed, it has
already been used for the synthesis of nanoparticles and nanospheres [Bodnar et al.
2005]. Furthermore, various ligands can be conjugated to chitosan via its amine side
groups. As such, it was viewed as an ideal envelope material. However, the use of
chitosan proved to be problematic, and due to reason that will be discussed in chapter
two, its use in the nanocell was abandoned.
The second project was undertaken to improve the spatial tumor targeting of the
nanocell. Tumor cells of varying type are known to overexpress certain cell-surface
molecular receptors. For example, ErbB, HER-2/neu, EGFR, and the folate receptor are
known to be overexpressed varying types of tumors [Richter and Zhang, 2005].
Accordingly, we decided to incorporate receptor targeting into the envelope of the
nanocell in order to introduce an additional layer of tumor cell targeting beyond selective
diffusion. As proof-of-concept, folic acid was used as the targeting ligand, because it is a
common and readily obtainable molecule. More importantly, and ligand that can be
conjugated to an amine or hydroxyl functional group may be used as a targeting ligand in
the redesigned nanocell.
The third and most substantial project undertaken was the design of a
methotrexate prodrug that would improve the loading efficiency of the nanocell while
also introducing another layer of tumor-environment targeting. In order to create a
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consistently sized, highly loaded prodrug, a polyamidoamine dendrimer was used as the
core of the prodrug. The dendrimer was of the third generation, and contained thirty-two
hydroxyl surface-functional groups. Through these functional groups, methotrexate was
conjugated to the dendrimer via an ester bond. The ester linkage was chosen because
abundant cellular esterases would cleave the cytotoxic drug from the dendrimer. The
consistent size of the dendrimer (see chapter two), and its biological activity (see chapter
three), both corresponded to the goals.
Together, the work presented in the following chapters represents the design and
synthesis of components that will be used to improve the therapeutic index of the
nanocell, thereby moving the nanocell a step towards being used in a clinical setting.
With an inexpensive, efficient, biocompatible nanocell, the challenges facing
combination therapy can be overcome, and the full benefit of combining multiple cancer
treatment modalities can be realized.
Chapter One: Introduction
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Chapter 2
Synthesis Work
In chapter one, the design principles for a second-generation nanocell were
discussed. In pursuit of developing a nanocell drug delivery vehicle with enhanced
efficiency and tumor targeting properties, a number of conjugate molecules were
synthesized and analyzed. In what follows, the possibility of using chitosan in the
nanocell envelope is assessed, folate receptor targeting is incorporated into the envelope
polymers of the nanocell, a dendrimer-based prodrug is developed for loading the
nanocell with a slow-acting cytotoxic drug, and multiple cytotoxic drug conjugates are
synthesized as proof-of-concept-expandability.
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2.1 Folate-Chitosan Conjugates
2.1.1 Introduction
Initially, the research focused on the creation of chitosan-based conjugates for use
in the nanocell envelope. Chitosan is an established biocompatible material, and it
exhibits many properties that make it an attractive choice for an envelope component.
* Chitosan is a cationic polysaccharide that has been used widely to encapsulate
pharmaceuticals for transport in the bloodstream. Such properties are desirable if
one expects to create a stable vesicle for transport in a hydrophilic environment
such as the bloodstream.
* Chitosan also contains hydroxyl and primary aliphatic amine side groups. These
groups can be used as conjugation sites in the incorporation of tumor-targeting
ligands, as discussed in chapter one.
* Chitosan is very abundant in nature, and therefore it is inexpensive and easily
obtained.
In the following experiments, folate was conjugated to chitosan with the eventual
hope of synthesizing vesicles consisting of both chitosan and folate-chitosan conjugates.
As is common procedure in liposome design, a polyethylene glycol-disteroyl
phosphatidylethanolamine (PEG-DSPE) copolymer can be incorporated into the chitosan
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envelope in order to avoid uptake of the liposome by the Kupffer cells of the liver, and
thereby prolong nanosome circulation time and avoid [Wu and Zern, 1996].
2.1.2 Materials and Methods
Folic acid-chitosan (FA-CS) conjugates were synthesized as follows: 0.1 mmol
folic acid and 0.25 mmol ethyldimethylaminopropyl carbodiimide (EDC) were dissolved
in 2 mL dimethyl sulfoxide (DMSO) for 1 hour. The solution was then added to 5 mL of
1% (weight/volume) medium molecular weight chitosan (150 kDa) in 0.2 M acetate
buffer (pH 4.7). In parallel, the same reaction was carried out in 0.4 M acetate buffer (pH
4.7). The reaction was quenched after 24 hrs by bringing the reaction mixture to pH 9.0
via drop wise addition of 1% sodium hydroxide. DMSO, EDC, and unreacted folic acid
were removed by dialysis against phosphate buffer (pH 7.4) and water, for 2 days each.
The purified product was lyophilized to yield a light yellow, fluffy solid. [Mansouri et
al., 2006]
2.1.3 Results and Conclusions
The dried product was analyzed using UV absorbance spectroscopy at 368 nm.
For analysis, the sample was re-dissolved in acetate buffer. To re-dissolve the samples, it
was necessary to ultrasonicate them at a power of 220 watts, for approximately 15
seconds each. A comparison of the UV absorbance readings to a folic acid standard
curve allowed the amount of FA-CS conjugation to be determined. Assuming that the
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Figure 2.1: Ultraviolate absorbance (368 nm) studies of the product of the reaction to
synthesiize medium molecular weight chitosan (MMW, 150 kDa) conjugated to folic acid.
The reaction proceeded as described in the text, in 0.2 M and 0.4 M acetate buffers. Using
the linear region of the folic acid standard curve, folic acid concentrations of 0.39 mM and
0.38 mM are observed for the reactions in 0.2 M and 0.4 M acetate buffer, respectively. 0.5
mg/ml of sample (3.33 pM) was used for the studies, implying that the conjugation efficiency
was approximately one folate molecule per 7.25 chitosan (MMW) subunits. Note that the
linear region does not extend beyond 0.31 mM. The system was blanked with 5 mM acetate
buffer (pH 5.5), and all samples were dissolved in the same buffer.
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final product was purified to contain only chitosan and FA-CS, the UV studies revealed
that the conjugation succeeded, with roughly one folate molecule per 7.25 chitosan
subunits (Figure 2.1).
2.2 Chitosan and Folate-Chitosan Nanosomes
2.2.1 Introduction
The goal of the research with chitosan was to use the polysaccharide to
encapsulate therapeutic compounds. In accordance with this goal, the synthesis of
chitosan nanosomes was attempted. The gelation method was selected for this synthesis,
primarily because of its simplicity and effectiveness with chitosan.
2.2.2 Materials and Methods
The synthesis of chitosan nanoparticles was attempted following the ionic
gelation method, described in [Calvo et al., 1997]. 7.1 and 7.3 mg of chitosan and FA-
CS, respectively, were each added to 5 mL of 1.75 mg/mL acetic acid. The resulting
mixture was ultrasonicated at 220 watts for 10-15 seconds to form a solution. To these
solutions, 2 mL of 0.735 mg/mL sodium tripolyphosphate (TPP) was added drop wise.
Thus, the final concentrations of chitosan, acetic acid, and TPP were 1 mg/mL, 1.75
mg/mL, and 0.21 mg/mL, respectively. The solutions were set on medium stir for 2 hrs.
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2.2.3 Results and Conclusions
After the experiment completed, the solutions were analyzed by light scattering
spectroscopy. Particles of a 158.4 nanometer radius were obtained for the chitosan-only
protocol, and a mixture of particles with 246.2 and 1871.1 nanometer radii were obtained
for the folate-chitosan protocol. Scanning Tunneling Microscopy (STM) was also
attempted, though it revealed chitosan clumps rather than nanoparticles. However, it
should be noted that a lyophilizer was used to transition the nanoparticle to the solid
phase for the STM experiments; it is likely that the process of lyophilization caused the
destruction of the nanoparticles.
Though light scattering spectroscopy did return a reasonable radius for the
particles in solution, it cannot be used to infer that the particles are indeed spherical
and/or hollow. For this matter, a direct form of visualization, such as transmission
electron microscopy (TEM), is required. However, assuming that the nanoparticles were
of the desired shape, they were still larger than desired. The final size of the
nanoparticles is highly dependent on the concentrations of chitosan and TPP in the
gelation method [Calvo et al., 1997], so further experiments would be necessary in order
to optimize the gelation method to our needs.
In general, working with chitosan was difficult. As mentioned previously, it was
often necessary to use ultrasonication when dissolving the chitosan conjugates.
Unfortunately, the energy introduced by ultrasonication readily breaks polysaccharide
chains, and therefore introduces additional variables to the experiment [Tang et al.,
2003]. In addition to being a studied side effect of ultrasonication, the breakage of the
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polysaccharide manifested experimentally, in the inconsistently sized chitosan
nanoparticles.
The size inconsistency discussed would introduced uncertainty in nanocell
loading and therefore in the dosage of the delivered drugs. Thus, the immediate benefit
of using chitosan did not outweigh the difficulty of working with the material, and a
decision was made to forego the use of chitosan and to focus on incorporating folate
receptor targeting into the original nanocell envelope.
2.3 Cisplatin Analogue and PLGA Conjugate
2.3.1 Introduction
Cisplatin is an established cytotoxic drug that is used in the treatment of some
types of cancer. The biomolecule induces apoptosis in cells by binding to a number of
targets, including DNA, cell membrane phospholipids, and different cytoplasmic and
membrane: proteins [Gonzales et al., 2001; Fuertes et al., 2003]. In this study, an analog
was synthesized and bound to PLGA. The conjugate serves as another novel cytotoxic
conjugate that may be used in constructions of engineered particles such as the nanocell.
The research on the cisplatin-analog conjugate was lead by and is continuing in the hands
of Dr. Geeti Gangal.
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2.3.2 Materials and Methods
Step 1 1,3-dibromo-2-propanol was stirred with sodium azide in a 1:3 molar
ratio, in anhydrous dimethylformamide (DMF) as the solvent (15 mL DMF per ig 1,3-
dibromo-2-propanol). The reaction was carried out at 50°C for 24 hrs, after which the
product was extracted using ethyl acetate and washed 3x each with water and brine
(10%). The solvent was evaporated to yield 1,3-diazido-2-propanol (see Figure 2.2).
Step 2. lg of 1,3-diazido-2-propanol was reacted with 150g 10% Pd/C catalyst in
100 mL methanol under hydrogen atmosphere. The reaction was monitored using TLC
(3:1 hexane:ethyl acetate, then dipped in ninhydrin and heated) and carried out until
completion (7-8 hrs). Purification yielded 1,3-diamino-2-propanol (see Figure 2.2).
Step_3: 1,3-diamino-2-propanol was dissolved in water (50 mg/mL) and treated
with potassium tetrachloroplatinate in 1:1 molar ratio. The solution was filtered and then
stirred for 24 hrs at room temperature. Refrigeration for 24 hrs resulted in the
precipitation of a yellow-brown solid - the cisplatin analogue - which was filtered and
dried.
Step_•. A cisplatin-PLGA conjugate was synthesized in the following way. 37.8
mmol (1 equiv.) of activated poly(lactic-co-glycolic acid) was dissolved in DMF (30
mg/mL) tunder nitrogen atmosphere. To the solution, 1.6 equiv cisplatin analogue, 1
equiv. 4-dimethylaminopyridine (DMAP) and 4 equiv. of triethylamine (TEA) were
added. The reaction was carried out under nitrogen atmosphere for 24 hrs. The reaction
solution was added drop wise to 100 mL diethyl ether in order to precipitate the product.
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After allowing the ether to stir slowly overnight, in the dark, the ether was decanted and
the product was re-dissolved in methylene chloride. The resulting solution was washed
twice in a 0.1% HC1 + 10% brine solution, dried, and re-precipitated in ether. After slow
stirring overnight, the ether was decanted. The product was collected in vials and placed
in a vacuum desiccator to dry.
2.3.3 Results and Conclusions
A cisplatin analogue and its PLGA conjugate were successfully synthesized, and
testing to determine the biological activity of both will be performed outside of the scope
and timeframe of this thesis. The conjugate represents a move to incorporate different
cytotoxic drugs into the nanocell framework. Such testing is necessary because cancer is
a highly variable disease - unique treatments are necessary for different types of tumors.
In the context of the nanocell, it is important to keep in mind that this variability affects
all layers of the nanocell: differing tumor types express different cell surface receptors,
respond to different anti-angiogenesis drugs, and have varying sensitivities to the plethora
of cytotoxic compounds available [Yong et al., 2006; Undevia et al., 2005]. The medical
literature is an excellent guide to such variation, and the matching treatments currently
used.
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Figure 2.2: Proton NMR confirmation of successful steps towards the synthesis of a cis-
platin analogue. The synthesis of 1,3-diamino-2-propanol from 1,3-diazido-2-propanol was
confirmed by the appearance of the coupled double doublets at J = 2.59 ppm and the con-
version of a quintet at 6 = 3.95 ppm to a septet at J = 3.54 ppm.
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2.4 FA-PEG-DSPE Conjugates
2.4.1 Introduction
In designing the envelope of the nanocell, several factors must be taken into
account. First, the envelope must be hydrophobic enough in order stably encapsulate
therapeutics in a manner reminiscent of a cell membrane. Second, the nanocell should
remain stable in the blood stream. Second, the lipophilicity of the nanocell must be
controlled such that it is not rapidly endocytosed by the Kupffer cells of the liver.
In the pilot project, polyethylene glycol (PEG) - disteroyl phosphatidyl-
ethanolamine (DSPE) copolymers were incorporated into the envelope in order to
decrease the nanocell's surface hydrophobicity. When used in liposomes, the copolymer
introduces a negative surface charge [Webb et al., 1998]. Thus, our goal in this portion
of the research was to develop a tumor targeting FA-PEG-DSPE conjugate that could be
used in the envelope of the next-generation nanocell.
2.4.2 Materials and Methods
Synthesis of FA-PEG-NHg (Figure 2.3): FA-PEG-NH 2 was synthesized from
bis(aminoethyl) PEG in the following way. 0.1 mmol (200 mg) of bis(aminoethyl) PEG
was dissolved in 2 mL DMSO with 4 juL pyridine. 1 molar equivalent of folic acid and
dicyclohexylcarbodiimide (DCC) were added to the reaction vial, and the solution was
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Figure 2.3: Proposed reaction route for the synthesis of the FA-PEG-NH 2 conjugate.
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stirred in the dark for 24 hrs. After 24 hrs, 2 mL water was added to the reaction,
dicyclohexylurea (DCU) was precipitated from solution. DCU was removed by
filtration, and the filtrate was then dialyzed against 5 mM ammonium bicarbonate (pH
9.0) and water. After dialysis, the product was lyophilized to remove excess solvent.
[van Steenis JH et al., 2003]
To purify FA-PEG-NH2 from bis(aminoethyl) PEG, a cellulose phosphate cation
exchange resin was prepared. Initially, column chromatography purification was
attempted using the column. The product formed a visible yellow band, but it did not
elute with varying concentrations (up to 10 mM) of ammonium bicarbonate as the eluant.
Later, a batch adsorption technique was used: the lyophilized product was mixed with the
prepared cellulose phosphate resin in 10 mM ammonium bicarbonate for 1 hr. The
mixture was then centrifuged and filtered to remove the cellulose phosphate, and
lyophilized to yield a light yellow solid (9.6 mg).
Synthesis of FA-PEG-NHS (Figure 2.4): Following the synthesis of FA-PEG-
NH2, the synthesis of FA-PEG-NHS was attempted. FA-PEG-NH 2 was dissolved in
DMSO at a concentration of 10 mg FA-PEG-NH2 per (1 mL DMSO + 0.8 pL TEA). To
this solution, 10 equiv. of disuccinimidyl suberate (DSS) was added, and the reaction was
carried out overnight, in the dark. To isolate the product, the reaction mixture was added
drop wise to ether and stirred slowly for 3.5 hrs. The ether was decanted, and the
remaining precipitate was re-dissolved in methylene chloride. After vacuum evaporation
to remove methylene chloride, a clear, oily liquid remained. However, this liquid was not
the desired product (see results section).
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Synthesis of N-succinyl DSPE: The synthesis of N-succinyl DSPE was attempted
by mixing 100 mg DSPE (1 equiv.) and 1.1 equiv. of succinic anhydride in 5 mL
chloroform, with 1yL pyridine per 1 mL chloroform. However, DSPE and succinic
anhydride did not dissolve in chloroform or in a variety of chloroform:methanol
solutions. The reactants were allowed to react overnight, as a mixture, but no reaction
was observed. No reasonable amount of pure product could be obtained from the
solution component of the mixture. Instead, the starting material was recovered and
stored. It was hoped that the synthesis depicted in Figure 2.5 could be executed. [Lee
and Low, 1995].
Synthesis of FA-PEG-DSPE: Ultimately, FA-PEG-DSPE was synthesized from
purchased NH2-PEG-DSPE [Gabizon et al., 1999]. 7.1 jmol NH 2-PEG-DSPE and 1.75
equiv. of folic acid were dissolved in 200 yL and 100 pL DMSO, respectively. 100 ~L
pyridine and the folic acid solution were added to the reaction flask containing NH2-
PEG-DSPE. Shortly afterwards, 4.5 equiv. of DCC was added, and the reaction was
stirred in the dark and monitored using TLC. The reaction was completed after 5.5 hrs.
Water was added to the reaction flask, and DCU was precipitated from solution. DCU
was removed by centrifugation (9000 RPM, 5 min), and the remaining unwanted reaction
material was removed by dialysis against 50 mM sodium chloride and water. The full
reaction route is shown in Figure 2.5.
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Figure 2.6: Ultraviolate absorbance (368 nm) studies of the product of the reaction to
synthesiize FA-PEG-NH 2. The concentration of folic acid was determined to be 0.29 mM.
The system was blanked with 10 mM ammonium bicarbonate buffer (pH 8.85), and all
samples were dissolved in the same buffer.
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Figure 2.7: Ultraviolate absorbance (368 nm) studies of the product of the reactions to syn-
thesiize FA-PEG-NH 2 and FA-PEG-DSPE. The concentrations of folic acid were determined
to be 0.34 mM and 0.14 mM, respectively. Sample concentrations of 0.7 mg/ml were used in
the studies - one would expect the observed concentrations of folic acid in the FA-PEG-NH 2
and FA-PEG-DSPE samples to be 0.29 mM and 0.22 mM, respectively, in the case of a 1:1
folic acid:polymer conjugation. Thus, conjugation efficiencies of approximately 117% and
63% (FA-PEG-NH 2 and FA-PEG-DSPE, respectively) were obtained; implicit is the over-
conjugation of NH 2-PEG-NH2 (monoconjugation was desired). The system was blanked with
10 mM ammonium bicarbonate buffer (pH 8.85), and all samples were dissolved in the same
buffer.
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2.4.3 Results and Conclusions
The purified, folate-conjugated solid was analyzed using UV absorbance
spectroscopy (368 nanometer wavelength) in conjunction with a linear folic acid standard
curve. The analysis suggested that 71-72% of the final solid in the FA-PEG-NH 2
synthesis was successfully folate conjugated (see Figure 2.6); the remaining 30% of the
sample was either bis(aminoethyl) PEG, light-exposed FA-PEG-NH 2, or other impurity.
Additionally, some of the folate-conjugated solid may have been doubly conjugated.
Indeed, a repeat synthesis, in which the reaction proceeded for six additional hours and
under well-maintained darkness, resulted in a conjugation efficiency of 117% (Figure
2.7).
A UV absorbance scan was performed on the product of the FA-PEG-NHS
synthesis in order to determine if either one of folate or the NHS active group was
present. The scan revealed that none of the expected absorbance peaks were present. If
the product were FA-PEG-NHS, absorbance peaks would have been observed at 270 and
368 nanometer wavelengths, due to the NHS and folate groups, respectively.
UV absorbance spectroscopy at 368 nanometers was also used to analyze the
product of the FA-PEG-DSPE synthesis. Under the assumption that the final product was
purified well enough to be only FA-PEG-DSPE or NH2-PEG-DSPE, the UV studies
suggested that 63% of the product was folate-conjugated (see Figure 2.7).
The yield of the reaction FA-PEG-NH 2 synthesis reaction was very low, and the
subsequent FA-PEG-NHS step did not proceed as expected. After the purification of FA-
PEG-NH2 and the synthesis of N-succinyl DSPE from basic components proved to be
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difficult, a decision was made to synthesize the envelope components using starting
materials that are closer to the desired product (i.e. NH2-PEG-DSPE, as described
above).
2.5 Methotrexate-PAMAM Prodrug
2.5.1 Introduction
In the drive to develop an effective and efficient way to load the nanocell with
slow-release cytotoxic drugs, dendrimers offer many unique capabilities. First, because
dendrimers are highly branched molecules with numerous terminal groups, they can bind
several ligands per molecule. For example, a single third generation PAMAM dendrimer
can bind a theoretical maximum of thirty-two terminal ligands, whereas a linear molecule
can bind only two such ligands. Second, because dendrimers are highly symmetric and
are synthesized in a controlled manner, there is minimal variation in the final size of the
dendrimer-drug conjugate. In the following experiments, methotrexate (MTX) was
conjugated to a third generation PAMAM dendrimer to form a prodrug. An ester bond
anchors MTX to the dendrimer; esterase enzymes in tissue readily cleave this bond.
Because esterase enzymes are upregulated when cells are stimulated to degrade the
extracellular matrix and migrate, as they do in hypoxic tumor microenvironments
[Pennacchietti S. et al., 2003], the dendrimer should display the preferential release of
methotrexate in the hypoxic environment brought about by anti-angiogenesis therapy.
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2.5.2 Materials and Methods
2.84 pmol of a third generation PAMAM dendrimer with terminal hydroxyl
groups was dissolved in 165 pL anhydrous DMF. Separately, 32 equiv. methotrexate
(MTX) and 32 equiv. CMPI were dissolved in 500 ,L and 165 pL of anhydrous DMF,
respectively. The MTX solution was added to the dendrimer solution, and 64 equiv.
triethylamine (TEA) was added to the reaction mixture. The CMPI solution was then
added, and the reaction was stirred for 24 hrs at 40*C. After 24 hrs, the reaction mixture
was dialyzed against 10 mM ammonium bicarbonate buffer to purify the dendrimer
conjugates. During dialysis, a brown precipitate formed periodically, and was broken up
manually. After dialysis, the product was lyophilized to yield a brown solid. The
reaction route is shown in Figure 2.8.
2.5.3 Results and Conclusions
The PAMAM-MTX conjugate was analyzed using UV absorbance spectroscopy
at a 380-nanometer wavelength and a linear methotrexate standard curve. UV
spectroscopy showed approximately 68% conjugation (see Figure 2.9), and NMR
spectroscopy corroborated these results (see Figure 2.10). A repeat experiment
demonstrated similar conjugation efficiencies. Transmission electron microscopy
showed that the PAMAM-MTX conjugates were all approximately 10-12 nanometers in
diameter (see Figure 2.11), and displayed radial symmetry, as expected.
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Figure 2.8: The proposed reaction route for the conjugation of methotrexate to a G3 polyami-
doamine dendrimer. Note that not all of the thirty-two potential methotrexate ligands are
shown in the final conjugate - have of the ligands are omitted for ease of display.
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Figure 2.9: Ultraviolate absorbance studies of the product of the reactions to synthesiize
the methotrexate-(G3)polyamidoamine conjugate. The absorbance studies were conducted
at 300 and 380 nm. However, only the 380 nm data set provided an usable methotrexate
standard curve. After testing the absorbance of several different dilutions of the sample
(throughout the range of the standard curve), the conjugation efficiency of the reaction
was determined to be approximately 69%. The efficiency was highly reproducible (data not
shown), indicating that further conjugation was likely hindered by steric effects. The system
was blanked with DMSO, and all samples were dissolved in DMSO.
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Figure 2.10: Proton NMR studies of the methotrexate-(G3)polyamidoamine conjugate. The
results of the ultraviolet studies are confirmed by integration of the small peaks: the ratio
of the terminal hydroxyl signal (broad 'H-shift peak at 6 = 4.78 ppm), representing the
unconjugated terminal end of the polyamidoamine dendrimer, to an aromatic C-NH2 signal
(one of the two broad 'H-shift peaks between 6 = 6.65 ppm and 6.9 ppm), representing
methotrexate ligand, is approximately 0.45.
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Figure 2.11: Transmission electron microscopy of the methotrexate-(G3)polyamidoamine
conjugate. The x-axis scale is 300 nm. The conjugates, as shown, have radial symmetry and
range from 10-12 nm in diameter.
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The PAMAM-MTX conjugation was successful, though not 100% efficient. It is
likely that steric effects prevented the complete conjugation of thirty-two methotrexate
molecules to each PAMAM dendrimer. In cell studies performed by Dr. Sujan Kabir,
which will be described in chapter three, the conjugate was shown to have anti-tumor cell
activity. Additionally, the dendrimer prodrug showed enhanced potency in hypoxic
cellular environments. Thus, in addition to developing an efficient cytotoxic drug-carrier
for the loading of the nanocell, another layer of spatial targeting was successfully
incorporated into the nanocell design. Though each spatial tumor targeting layer in the
nanocell - selective extravasation, receptor targeting, and hypoxia-enhanced drug release
- is by no means 100% specific to the tumor microenvironment, each tumor-preferring
layer should build upon the others to improve the therapeutic index of the nanocell.
2.6 PD98059 Amide Linkage to Aromatic Amine
2.6.1 Introduction
To further develop cytotoxic dendrimer-based prodrugs similar to the MTX
conjugate described above, the conjugation of a MAPK kinase inhibitor, PD98059, to
PAMAM was explored. In evaluating possible reaction routes, the basic requirement was
that the reaction result in the formation of an ester bond. As discussed above, an ester
bond would allow for the in vivo esterase-mediated release of the bound drug.
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Several reactions were considered and/or tested, and rejected on the basis of
difficulty and potential toxicity. Ultimately, it was decided that a conjugation reaction
involving the sulfhydryl-activation of the amine group of PD98059 would be ideal. After
the activation step, the prodrug can be synthesized via a conjugation reaction involving a
heterobifunctional (maleimide-N-hydroxysuccinimide) crosslinker, activated PD98059,
and the PAMAM dendrimer.
2.6.2 Materials and Methods
The PD98059 activation was carried out as follows. 0.0374 mmol PD98059 was
dissolved in 400 pL DMSO. To the resulting solution, 1 equiv. TEA and 10 equiv. 2-
iminiothiolane-HC1 was added, and the reaction was stirred and monitored by TLC.
After 24 hrs, the reaction mixture was dialyzed against 25 mM sodium borate buffer (pH
9.0) and water for 2 days each. The resulting mixture was lyophilized and analyzed with
NMR spectroscopy.
2.6.3 Results and Conclusions
TLC monitoring showed that the activation of PD98059 occurred slowly.
However, the reaction did occur, as can be confirmed by the appearance of a sulfhydryl
peak in the 1H NMR spectrum of the product (see Figure 2.12). In conjugating different
drugs to the dendrimer, careful consideration must be given to both the cross-linker used
and the reaction route taken to conjugation. The cross-linker and reaction route must
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Figure 2.12: Proton NMR study of the cytotoxic compound PD98059, a MAPK kinase in-
hibitor, after being activated with a sulfhydryl group. The reaction did not go to completion,
but the appearance of a 1H peak at 1.59 ppm on the NMR spectrum above indicates the
successful sulfhydryl activation of PD98059. Upon successful activation, PD98059 may be
conjugated to the G3 polyamidoamine dendrimer via an ester bond by using any one of a
number of heterobifunctional crosslinkers (i.e. maleimidoethyl succinimidyl succinate).
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allow for a reaction of acceptable efficiency to take place, an ester bond to be formed
somewhere between the drug and the dendrimer, and for the cytotoxic compound to
maintain its bioactivity upon its esterase-mediated cleavage from the dendrimer.
2.7. Summary
The work described above has focused on the synthesis of the basic components
of the second-generation nanocell. The initial objective to use chitosan in the nanocell
envelope was abandoned due to the difficult and time-consuming task of working with
the material. Furthermore, the non-economic benefits of using chitosan were not entirely
unique: a biocompatible envelope had already been designed and synthesized in the pilot
study. As such, the focus of the research shifted from developing a chitosan-based
envelope to incorporating folate receptor targeting into the original nanocell envelope.
To incorporate folate receptor targeting into the original envelope, different synthetic
routes to the desired conjugates were considered. Ultimately, the synthesis of FA-PEG
and FA-PEG-DSPE conjugates succeeded, and was found to be most efficient and
economical with fewer reaction steps. Upon synthesizing these conjugates, the research
shifted to developing a novel loading mechanism for the nanocell.
To achieve the goal of creating a more efficient loading mechanism, a dendrimer-
based prodrug was synthesized. Methotrexate was conjugated to a third-generation
PAMAM dendrimer through an ester bond with a reproducible efficiency of 70%; the
dendrimer-drug conjugates were 10-12 nanometers in diameter and bioactive. Reaction
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routes to linking other cytotoxic drugs (i.e. PD98059) to the dendrimer via an ester bond
were also explored and identified. The dendrimer prodrug, combined with the folate
receptor-targeting envelope, stands to advance the nanocell to a unique level of
effectiveness. In the following chapter, the denrimer prodrug is shown to be bioactive,
while also displaying preferential release of the bound cytotoxic drug in hypoxic
microenvironments.
The robustness in the design of the nanocell is extremely important. As
mentioned earlier, different tumors and different individuals require uniquely optimized
treatments. Such is the nature of today's increasingly personalized form of medical
treatment, and the nanocell must accommodate. Accordingly, any receptor-targeting
ligand that can be linked to hydroxyl or amine functional groups, either on its own or
using a crosslinker, can be incorporated into the envelope of the nanocell. Similarly, any
cytotoxic drug that can be conjugated via an ester bond to the hydroxyl functional group
of the dendrimer can be used in the present design of the nanocell. Thus, incorporating a
variety of treatments into the framework of the nanocell is a matter of chemistry, while
the underlying strategic design of the nanocell may remain constant.
Chapter Two: Synthesis Work
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Chapter 3
Cell Studies
Following the synthesis of the methotrexate-(G3)polyamidoamine dendrimer
described in chapter two, cell studies were performed to assess the biological activity of
the prodrug. The studies were designed and executed by Dr. Sujan R. Kabir. The
studies reveal that the prodrug does indeed have a cytotoxic effect, and this effect is
enhanced in hypoxic cellular microenvironments. The studies were performed on Lewis
Lung Carcinoma cells.
3.1. Protocol
The protocol developed by Dr. Kabir was performed on Lewis Lung Carcinoma
cells purchased from ATCC (#CRL-1642). The medium used was 90% Dulbecco's
modified Eagle's medium (with 4 mM L-glutamine and 1.5 g/L sodium bicarbonate) and
10% fetal bovine serum. The stock solution is typically prepared using 450 mL DMEM
high glucose, 50 mL fetal bovine serum, 5 mL sodium bicarbonate, 5 mL glutamine, and
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5 mL pen-strep. Upon mixing, the stock solution is filtered through a 0.45 micron
filtration unit and stored at 40 'C.
The flasks used for growing and maintaining the cells is pretreated for 4 hours
with a sterile 0.1% cell culture gelatin solution in deionized water; the gelatin is aspirated
before plating the cells. A 85-90% confluent cell source flask is trypsized with 1 mL
solution, and after 1-2 minutes, the trypsin is neutralized with 6-7 mL of LLC media.
The mixture is made homogenous by pipetting. The cell solution is spun down at 2000
rpm for 5 minutes, and the pellet is resuspended in 6-7 mL media. Cells are counted, and
2.5 x 205 cells are plated in a new gelatin-coated flask. After the cells become confluent
(typically 2-3 days), plating for the experiment may begin.
In plating Lewis Lung Carcinoma (LLC) cells, two flasks are used: one with
normal LLC cells in media, and second with hypoxic LLC cells. Hypoxia is induced via
the incubation of normal LLC cells in media with 100 PM CoCl2 for 12-16 hours before
plating.
For the experiment, different 96 well plates are used. The plates are pretreated for
4 hours with sterile solution of 0.1% cell culture gelatin in deionized water; the gelatin
solution is aspirated before plating. In each well, 1000 LLC cells are plated in 100 pM
media, and the cells are incubated for 6 hours in order to allow attachment. At time point
zero, the cells are treated with DMSO, free and conjugated methotrexate (DMSO is the
vehicle).
The cells are treated with control (zero), 0.001, 0.01, 0.1, 1, 10, and 100 pM
concentrations of methotrexate, methotrexate-(G3)PAMAM conjugate, and the vehicle
DMSO. LLC cell proliferation is monitored by counting the number of cells in each well
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at the 24, 36, 48, 60, and 72 hour time points, using a MTT assay. The data is collected
and cross-compared in order to determine the biological effect of the methotrexate-
PAMAM(3G) conjugate on tumor cells in hypoxic and normal media.
3.2. Results
In the assay performed by Dr. Kabir, cell proliferation was monitored and
reported as the percentage of cells counted at a given time point relative to initial number
of cells (1000 in the protocol described above).
Figure 3.1: At the 24 hour time point, there was little difference in cell
proliferation among normal LLC cells treated with DMSO, methotrexate, and the
methotrexate-(G3)PAMAM conjugate. However, with hypoxic LLC cells, both
methotrexate and the methotrexate conjugate had an inhibitory effect on cell proliferation
relative to the vehicle. The effect of free methotrexate was the strongest, though the
relative inhibitory effect of both disappeared at higher concentrations, indicating that, at
high concentrations, the inhibitory effect was dominated by DMSO.
Figure 3.2 At the 36 hour time point, free methotrexate showed a significant
inhibitory effect on normal LLC cell proliferation relative to the vehicle DMSO. The
effect was not observed with the methotrexate conjugate except at high (100 YM)
concentration. With hypoxic cells, however, both free and conjugated methotrexate had
an inhibitory effect on cell proliferation. The effect was consistently stronger with free
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methotrexate, across all tested non-zero concentrations.
Figure 3.3: At the 48 hour time point, free methotrexate again showed a
significant inhibitory effect on normal LLC cell proliferation relative to the vehicle
DMSO. However, the effect was not clear at concentrations lower than 0.1 UM. Beyond
0.1 pM, the inhibitory effect of free methotrexate on cell proliferation was stronger with
increasing concentration. The methotrexate conjugate also inhibited cell proliferation
relative to DMSO, and it did so at concentrations of 10 and 100 pM (the inhibition was
slightly stronger at 100 pM). With hypoxic cells, free methotrexate clearly had an
inhibitory effect on cell proliferation that was stronger at higher methotrexate
concentrations. The methotrexate-(G3)PAMAM conjugate did not show an inhibitory
effect relative to DMSO until a concentration of 1 pM. The effect was then increasingly
strong with 10 and 100 pM concentrations of the conjugate.
Figure 3.4: At the 60 hour time point, free methotrexate showed a significant
inhibitory effect on normal LLC cell proliferation relative to the vehicle DMSO. The
effect was clear at concentrations greater than 0.001 pM, and the inhibitory effect of free
methotrexate on cell proliferation was stronger with increasing concentration. The
methotrexate conjugate again inhibited cell proliferation relative to DMSO, and it did so
significantly at concentrations of 10 and 100 pM (the effect was similar in magnitude).
With hypoxic cells, free methotrexate had an inhibitory effect on cell proliferation that
was stronger at higher methotrexate concentrations, but leveled out after 1 pM. Again,
the methotrexate conjugate did not show an inhibitory effect relative to the vehicle until a
concentration of 1 pM; beyond 1 #M, the effect was stronger with increasing
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concentration.
Figure 3.5: At the 72 hour time point, free methotrexate showed a significant
inhibitory effect on normal LLC cell proliferation relative to DMSO. The effect was
clear at all concentrations, and was stronger with increasing concentration; however, it
leveled off after 1 /M. The methotrexate conjugate again inhibited cell proliferation
relative to DMSO, and it did so at all conjugate. As expected, the effect was stronger
with increasing concentration. With hypoxic cells, free methotrexate had an inhibitory
effect on cell proliferation that was stronger at higher methotrexate concentrations, but
again leveled off after treatment concentrations 1 /4M. The methotrexate conjugate
showed an inhibitory effect relative to the vehicle beyond treatment concentrations of
0.01 pM; again, the effect was stronger with increasing concentrations of the
methotrexate conjugate.
Figure 3.6: Taking a cross section of data 10 pM treatment concentrations and
following the effect through time, it is clear that the methotrexate conjugate has an
inhibitory effect on LLC cell proliferation. The inhibitory effect of the prodrug takes
place more slowly than it does with free methotrexate, and the effect is also weaker than
that of free drug across all time points.
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Figure 3.1: Action of methotrexate-(G3)polyamidoamine dendrimer on Lewis Lung Car-
cinoma cell proliferation in vitro. The 24 hour time point shows enhanced inhibition by
the conjugate relative to the vehicle and control in a hypoxic environment. As desired, the
inhibition effect from the conjugate is slowed and attenuated relative to free methotrexate.
Data obtained from experiments designed and performed by Dr. Sujan R. Kabir; used with
permission.
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Inhibition of LLC Cell Proliferation - 36 Hours
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Figure 3.2: Action of methotrexate-(G3)polyamidoamine dendrimer on Lewis Lung Carci-
noma cell proliferation in vitro. The 36 hour time point also shows significant inhibition by
the conjugate relative to the vehicle and control. Similar effects as described in Figure 3.1
are observed, albeit augmented. Data obtained from experiments designed and performed
by Dr. Sujan R. Kabir; used with permission.
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Inhibition of LLC Cell Proliferation - 48 Hours
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Figure 3.3: Action of methotrexate-(G3)polyamidoamine dendrimer on Lewis Lung Carci-
noma cell proliferation in vitro, after 48 hours of treatment. Similar effects as described
in Figures 3.1 and 3.2 are observed, though the effect of the vehicle DMSO begins to take
stronger effect. Data obtained from experiments designed and performed by Dr. Sujan R.
Kabir; used with permission.
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Inhibition of LLC Cell Proliferation - 60 Hours
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Figure 3.4: Action of methotrexate-(3G)polyamidoamine dendrimer on Lewis Lung Carci-
noma cell proliferation in vitro. The 60 hour time point also reveals an inhibitory effect
on LLC cell proliferation by the conjugate, relative to the vehicle and control. Again, the
inhibitory effect of the conjugate is slowed and attenuated relative to free methotrexate.
Compared to Figure 3.2, one can see quite clearly the slow-release effects of the methtrexate-
(G3)polyamidoamine conjugate. Data obtained from experiments designed and performed
by Dr. Sujan R. Kabir; used with permission.
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Inhibition of LLC Cell Proliferation - 72 Hours
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Figure 3.5: Action of methotrexate-(G3)polyamidoamine dendrimer on Lewis Lung Car-
cinoma cell proliferation in vitro at the final, 72 hour time point. Data obtained from
experiments designed and performed by Dr. Sujan R. Kabir; used with permission.
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Inhibition of LLC Cell Proliferation by Free and Conjugated Methotrexate (1OpM)
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Figure 3.6: Action of methotrexate-(G3)polyamidoamine dendrimer on Lewis Lung Car-
cinoma cell proliferation in vitro. Here, the data is displayed across time, for treatment
concentrations of 10 pm. The methotrexate conjugate has an attenuated, inhibitory effect
on cell proliferation. Furthermore, in comparing the effect of the conjugate to that of the
vehicle, it is evident that the methotrexate-(G3)polyamidoamine conjugate displays slow-
release characteristics in vitro. Data obtained from experiments designed and performed by
Dr. Sujan R. Kabir; used with permission.
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3.3 Conclusions and Future Experiments
The cell studies of the methotrexate-(G3)PAMAM conjugate show promising
results. First of all, the conjugate maintains bioactivity - methotrexate from the
conjugate inhibits LLC cell proliferation relative to the vehicle DMSO across all time-
points. The inhibitory effect is, as expected, slower than that of free methotrexate.
The cell studies also reveal that the methotrexate-dendrimer conjugate behaves
slightly differently in hypoxic and non-hypoxic environments. From the data presented
above, it can be seen that the cytotoxic effect of the conjugate is accelerated in hypoxic
environments; the cell studies at the 36-hour time point show this behavior most clearly.
However, the effect is diminished at later time points.
In considering these studies, it is important to note that the vehicle, DMSO, has a
significant inhibitory effect on LLC cell proliferation (for example, see figure 3.6). The
effect of the vehicle may obscure important behavior of the methotrexate-conjugate.
Though the cell studies were performed with the vehicle alone for a comparative analysis,
it will be important to determine the action of the conjugate in the absence of DMSO. To
overcome solubility problems, a slow release, encapsulating particle will be used in
future studies.
It should also be determined if the action of the methotrexate-(G3)PAMAM
conjugate is the result of esterase-mediated cleavage of methotrexate from the dendrimer.
An experiment that eliminates ester hydrolysis via others mechanism would aid in our
understanding of the true effect of the nanocell. In order to corroborate the argument that
the methotrexate-(G3)PAMAM conjugate selectively releases methotrexate in hypoxic
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cellular microenvironments, it would need to be shown that the upregulation of the
cleavage mechanism is indeed a result of hypoxia. Furthermore, a conclusive control
experiment demonstrating that the conjugate is not bioactive before cleavage should be
performed. Recent research has shown that covalent methotrexate-dendrimer conjugates
do have cytotoxic effects [Patri et al., 2005].
Keeping the future experiments in mind, these cell studies show that the
methotrexate-(G3)PAMAM conjugate is promising candidate for a novel loading
mechanism in a nanocell-based approach to cancer therapy. The nuclear magnetic
resonance, ultraviolet light absorbance, and transmission electron microscopy studies
presented in chapter two, combined with Dr. Kabir's cell studies here, show that the
conjugate is an efficient, slow-release drug delivery vehicle that is preferentially
bioactive in hypoxic cellular microenvironments. Furthermore, the conjugate is highly
consistent in its size and methotrexate carrying capacity.
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Chapter 4
Concluding Remarks
In the drive to develop effective cancer therapeutics, the nanocell is a very
promising concept. It is capable of both spatial and temporal tumor targeting, and thus it
can overcome several of the challenges faced by currently available cancer therapeutics.
First, relative to current intravenous administration of free drug, the nanocell isolates to
tumors and delivers only a minimal amount of drug to other parts of the body. In doing
so, the nanocell avoids many of the side effects of current chemotherapy. Second, the
temporally controllable release of the two drugs allows the nanocell to accumulate in the
tumor, attack the tumor vasculature, and then release chemotherapy drugs within the
tumor. Normally, anti-angiogenesis drugs must be administered for several days prior to
chemotherapy. Because the chemotherapy drug is delivered to the intratumoral space
during anti-angiogenesis therapy rather than after it, higher concentrations and pervasive
intratumoral release of the cytotoxic chemotherapy drug can be achieved despite the
diminished tumor vasculature. The higher intratumoral concentrations of chemotherapy
drug help overcome the HIF-la mediated stress responses described in chapter one.
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4.1 Accomplishments
In improving the nanocell to accommodate the demands of modem medicine,
several steps have been taken. First, folate receptor targeting was incorporated into the
nanocell envelope. Adding a receptor-targeting layer to the nanocell should allow it
target tumor cells with higher specificity than selective extravasation alone. Furthermore,
though the experiments were performed using folic acid as the targeting ligand, any
ligand may used with the nanocell; the crosslinking required is simply a matter of
chemistry. More importantly, an additional tumor-targeting layer - one can be adjusted
depending on the type of tumor being treated - has been added to the nanocell.
The second task undertaken was to develop a new loading mechanism for the
nanocell. With the general goal of making the nanocell industry viable, and therefore
very consistent and efficient, a dendrimer-based loading mechanism was chosen.
Dendrimers offer multiple ligand binding sites, as well as a very symmetric structure that
is controllable during synthesis. The dendrimer used in this thesis was a third generation
polyamidoamine dendrimer with thirty-two ligand-binding sites. The cytotoxic drug
methotrexate was conjugated to the dendrimer via the reaction route described in Figure
2.8, and the conjugation efficiency was approximately 70% (Figure 2.9).
Cell studies on the dendrimer demonstrated that it was indeed a bioactive
conjugate. The studies showed that the dendrimer exhibits a delayed inhibitory effect on
Lewis Lung Carcinoma cell proliferation, as desired. Furthermore, the inhibitory effect is
enhanced in hypoxic cellular microenvironments, implying that an additional layer if
tumor targeting may be successfully incorporated into future constructions of the
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nanocell.
Other work done throughout this thesis project served to demonstrate the
expandability of the nanocell concept. A vital aspect of the nanocell is that it is simply an
overarching design, a framework for delivering therapeutics to tumors. Because tumors
are highly variable, and especially so in the cell-surface receptors they over express and
the drugs that they are sensitive to, the nanocell must accommodate many different anti-
cancer drugs. The design of the nanocell, however, should consistently allow for the
improved delivery of any anti-cancer combination therapy, regardless of the anti-
angiogenesis or cytotoxic drugs used. As such, steps were taken towards constructing the
nanocell with different cytotoxic drugs.
Future work that will be done includes synthesizing the nanocell and testing it in
vivo. Such tests were performed with the first-generation nanocell, and naturally, they
must be performed with the second-generation nanocell as well. Only in vivo tests will
reveal the true effectiveness of the tumor targeting mechanisms designed into the second-
generation nanocell.
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4.2 The nanocell and other particle-based drug delivery vehicles
Much work has been done regarding the delivery of anti-cancer drugs to tumor
microenvironments. Several studies have focused on the use of nanoparticles [Brannon-
Peppas et al., 2004], liposomes [Sharma et al., 2006], functionalized micelles [Sutton et
al., 2007], and more [Reddy 2005] to deliver drugs to tumors. The impetus to use such
nanoscale delivery vehicles arises primarily from two sources: the enhanced permeability
and retention (EPR) effect of tumor microenvironments [Maeda et al., 2000], and the
ability to direct such vehicles to tumor cells using receptor-targeted ligands. Most
contemporary approaches to nanoparticle-based drug delivery deliberately take advantage
of one of these two motivating factors. The nanocell is unique in that it takes advantage
of both. Furthermore, the nanocell is designed to allow for a bolstered EPR effect, as it is
may be administered to the patient - without cytotoxic effect - while vascular
normalization takes place.
Thus, the nanocell represents a unique and forward-looking approach to tumor
targeted drug delivery. The nanocell's design incorporates a broad range of our current
understanding of cancer. From the unique cell biology of tumors to the important fluid
mechanical properties that such biology inevitably gives rise to, the nanocell takes
elements that may be seen as tumor-protective, and uses them to add layers of tumor-
targeting to the delivery and release of anti-cancer drugs. As research continues, the
ultimate vision is that the nanocell will allow for the synergistic combination of
inexpensive chemotherapy and anti-angiogenesis therapy, all while reducing the side
effects currently associated with such therapy.
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